Latest News of ROCR
Eurocrats plot to hobble US AI leadership on our own shores
By The Hill |
5 days ago
The European Union is expanding its regulatory reach into Silicon Valley to control American tech companies and impose compliance with EU regulations. This move threatens America's leadership in AI an...
Dopamine Detox: 3 Steps To Boost Focus And Beat Procrastination
By Forbes |
2 weeks ago
Consider a dopamine detox to combat procrastination and improve focus at work. By reducing high-dopamine activities like social media and gaming, you can reset your brain to prioritize long-term goals...
Overcoming Procrastination Via Generative AI
By Forbes |
1 month ago
Procrastination, often joked about, is a serious issue that can affect mental health. Generative AI can help combat procrastination by providing strategies and guidance. However, caution is advised as...
-
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
By Yahoo! Finance | 1 month agoNeurocrine Biosciences released positive Phase 2 data for NBI-1117568 in adults with schizophrenia, showing significant improvement with the 20 mg dose. Piper Sandler upgraded the stock rating, highli...
-
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History
By Yahoo! Finance | 1 month agoNeurocrine Biosciences disappoints investors with Phase 2 data on schizophrenia treatment. The study showed an 18.2-point reduction in symptoms with NBI-1117568 compared to 10.8 points with placebo, a...
-
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
By Investor's Business Daily | 1 month agoNeurocrine Biosciences' positive phase 2 trial results for a schizophrenia treatment fell short compared to competitors like Bristol Myers Squibb. Despite this setback, an expanded final-stage trial i...
-
Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)
By Yahoo! Finance | 1 month agoOn August 15, 2024, Director William Rastetter sold 14,250 shares of Neurocrine Biosciences Inc, owning 37,491 shares now. The company focuses on treatments for neurological and endocrine-related dise...
-
Neurocrine Biosciences Earns Relative Strength Rating Upgrade; Hits Key Benchmark
By Investor's Business Daily | 2 months agoDiscover how market breadth indicators like the Relative Strength (RS) Rating can uncover hidden weaknesses in a bull market. Learn how to evaluate stock performance and manage risks effectively by us...
-
Neurocrine Biosciences Shows Rising Price Performance With Jump To 81 RS Rating
By Investor's Business Daily | 2 months agoLearn how to find the best IPO stocks with IBD's RS Rating, tracking market leadership by comparing a stock's price action to others. Stocks with an RS Rating over 80 tend to perform well. Neurocrine ...
-
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 3 months agoNeurocrine Biosciences and Diurnal Ltd. showcased their neuroendocrinology pipeline at ENDO 2024, featuring primary data from Phase 3 studies of crinecerfont for congenital adrenal hyperplasia. Result...
-
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
By Investor's Business Daily | 3 months agoNeurocrine Biosciences (NBIX) shows strong performance, with a 36% profit increase last quarter and a recent RS Rating upgrade to 82. The company's flagship drug Ingrezza is a key driver, with a focus...
-
Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%
By Yahoo! Finance | 3 months agoNeurocrine Biosciences' stock has risen 55% in five years, below market average, but 39% in the past year. Shareholders have seen improved earnings, indicating potential growth, despite the market's s...